PT  - JOURNAL ARTICLE
AU  - Shunsuke Teraoka
AU  - Daichi Fujimoto
AU  - Munehiro Ito
AU  - Yoshihiro Nakagawa
AU  - Jiro Ito
AU  - Mariko Kogo
AU  - Yuki Sato
AU  - Kato Ryoji
AU  - Kazuma Nagata
AU  - Atsushi Nakagawa
AU  - Kojiro Otsuka
AU  - Yukimasa Hatachi
AU  - Keisuke Tomii
TI  - Intolarence of pirfenidone and its associated factors in the real world
AID  - 10.1183/13993003.congress-2016.PA786
DP  - 2016 Sep 01
TA  - European Respiratory Journal
PG  - PA786
VI  - 48
IP  - suppl 60
4099  - http://erj.ersjournals.com/content/48/suppl_60/PA786.short
4100  - http://erj.ersjournals.com/content/48/suppl_60/PA786.full
SO  - Eur Respir J2016 Sep 01; 48
AB  - [Background] Despite of evidences showing the benefit of pirfenidone, their use is frequently associated with some adverse effect which could result in discontinuation. We investigated the reason of intolerance and to identify predictors of tolerability to pirfenidone.[Methods] This retrospective study comprised 76 patients with pulmonary fibrosis who were treated with pirfenidone from January 2011 to January 2016. We evaluated the adverse effect affecting patient continuation of a stable maintenance dose.[Result] Nineteen of 76 failed to receive pirfenidone 1200mg/day. Anorexia was reported by eleven patients, which was largest population among the intolerance group. In the comparison to the tolerant group who succeeded in continuing more than 1200mg/day for a month, there was a significant association to prophylactic administration of dopamine receptor antagonists (38% vs 9%, p = 0.04).[Conclusion] This study reveal that anorexia is the most common reason for discontinuation of pirfenidone in the real world. Prophylactic administration of dopamine receptor antagonists provides a significant reduction of anorexia from pirfenione.